Tiburio is developing TBR-065, a dopamine-somatostatin chimeric compound, for the treatment of rare endocrine diseases.
Tiburio is also developing a second compound, TBR-065, for the treatment of rare endocrine disorders. TBR-065 is a dopamine-somatostatin agonist from the same family as TBR-760 and has been demonstrated to be safe and well-tolerated in clinical studies.
Tiburio is accumulating additional data to determine the optimal indication for TBR-065.
| Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|
|
Preclinical
|
Phase 1
|
Phase 2
|
Phase 3
|